Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Large B-Cell, Diffuse 12Recurrence 6Lymphoma, Non-Hodgkin 6Lymphoma, Mantle-Cell 6Lymphoma 6Lymphoma, B-Cell 4Dendritic Cell Sarcoma, Interdigitating 2Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Cytokine Release Syndrome 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Cyclophosphamide 23fludarabine 14Rituximab 14Specimen Handling 9Magnetic Resonance Spectroscopy 8Doxorubicin 7pirtobrutinib 6Vincristine 6Prednisone 6polatuzumab vedotin 5obinutuzumab 5Biopsy 5zanubrutinib 4glofitamab 4Nivolumab 4Etoposide 4Dexamethasone 4tazemetostat 3tafasitamab 3pembrolizumab 3ibrutinib 3fludarabine phosphate 3acalabrutinib 3Leukapheresis 3Bendamustine Hydrochloride 3venetoclax 2pomalidomide 2loncastuximab tesirine 2etoposide phosphate 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × glofitamab × 90 days × Clear all
NCT06634589 2026-06-03

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Active not recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

NCT07502872 2026-03-31

TPG

Brown University

Phase 2 Not yet recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

ADC Therapeutics S.A.

Phase 1 Recruiting
200 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡